TrialBlood advances2021

Next-generation sequencing-based monitoring of circulating tumor DNA reveals clonotypic heterogeneity in untreated PTCL.

Milos D Miljkovic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.